Insulin Price Manipulation: UnitedHealth Group and CVS at the Center of Controversy
Friday, 20 September 2024, 21:04
Price Manipulation in the Insulin Market
Federal authorities have accused three major pharmacy benefit managers (PBMs)—CVS-owned Caremark Rx, Cigna Group’s Express Scripts, and UnitedHealth Group's Optum Rx—of illegally inflating the price of insulin.
Impact on Patients and Competition
- Regulators allege that these companies use unfair rebating practices.
- This manipulation stifles competition for insulin drugs.
- Patients are facing challenges in accessing more affordable versions of this critical medication.
The Federal Trade Commission's findings raise serious concerns about healthcare practices within the industry.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.